Identification of research needs to resolve the carcinogenicity of high-priority IARC Carcinogens. Views and expert opinions of an IARC/NORA expert group meeting, Lyon, France, 30 June - 2 July 2009. Lyon, France: International Agency for Research on Cancer, IARC Technical Publication No. 42. 2010 Jul; 42:217-218
Some of the agents considered in this report consist of or may be produced as particles with at lease one dimension at the lower range of the nanoscale, particularly between 1 and 100 nm. Particles at this size have unique properties that are scientifically and commercially exploitable. They generally have more surface area per unit volume than larger particles of the same composition and are generally more biologically reactive, toxic and possibly carcinogenic than larger sizes. It will be important for investigators to consider particle dimensions in future research and to include particles in the range of 1-100 nm in research when appropriate (Schulte et al., 2009). In some cases, nanoscale materials may need to be evaluated separately from larger particles of the same chemical composition if the nanoscale materials could have different health effects. Critical in investigating the health effects of a nanoscale agent is attention to the metrics used in the research. It may be important to characterize exposure in various ways in addition to mass per unit volume. It may be important to use particle count and surface area as well. Also of importance is to consider the heterogeneity of nanoparticles. A large number of physio-chemical parameters can mitigate biological activity and toxicity and these should be considered in research and in comparing results of studies. Additionally, investigators should consider contaminants in nanoparticles and the degree of agglomeration in assessing exposure and biological effect (Schulte et al., 2009).
Cancer; Carcinogens; Carcinogenesis; Carcinogenicity; Particulates; Biological-material; Nanotechnology
Agriculture, Forestry and Fishing; Manufacturing
Identification of research needs to resolve the carcinogenicity of high-priority IARC Carcinogens. Views and expert opinions of an IARC/NORA expert group meeting, Lyon, France, 30 June - 2 July 2009